Receive our newsletter – data, insights and analysis delivered to you
  1. News
January 11, 2022

Fusion nominates first targeted alpha therapy under AstraZeneca partnership

According to a previous agreement, Fusion will oversee preclinical development through first-in-human trials of TATs.

Fusion Pharmaceuticals has nominated the first targeted alpha therapy (TAT) candidate under its partnership agreement with AstraZeneca to commence Phase I clinical trials.

The companies will co-develop the new TAT through a Phase I trial.

The new TAT leverages the Fast-Clear linker technology of Fusion to radiolabel an AstraZeneca-owned bispecific antibody with actinium-225 alpha-emitting isotope.

According to the prior partnership agreement, Fusion will handle the preclinical development through first-in-human trials while AstraZeneca will oversee the following clinical development. 

Fusion and AstraZeneca will split clinical development expenditures equally, with investigational new drug (IND)-enabling studies underway.

Fusion Pharmaceuticals CEO John Valliant said: “Fusion is at the forefront developing a new wave of cancer therapies using alpha-emitting medical isotopes and various targeting vehicles. 

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
Why Asia-Pacific is the next frontier for decentralized clinical trials

“One of the pillars of our platform is to create next-generation immunoconjugates, and we are excited to be working with AstraZeneca to pursue a novel radioimmunoconjugate for oncology. 

“We had strong alignment among our joint development committee to move this novel TAT forward into a planned Phase I study and we look forward to sharing more information as we approach the investigational new drug application (IND) filing.”

Fusion and AstraZeneca currently have a partnership for the co-development of up to three new TATs.

Up to five combination programmes would also be explored between TATs of Fusion and AstraZeneca’s DNA damage response inhibitors and immuno-oncology agents.

A lead programme of Fusion, FPI-1434 acts on the insulin-like growth factor 1 receptor and is presently being analysed in a Phase I trial. 

The company’s pipeline comprises FPI-1966 and FPI-2059, the latter being a small molecule acquired by Fusion from Ipsen.

Last December, AstraZeneca and Ionis Pharmaceuticals entered an agreement for the development and commercialisation of eplontersen.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU